Table 1.
Patient's characteristics entered into prospective study for high-risk patients (n = 162).
| Characteristic | WPRT + N-ADT (group A) | PORT (group B) | P* |
|---|---|---|---|
| Patients (n) | 70 (100%) | 92 (100%) | — |
| Mean age (years) | 68.1 (range: 47–78) | 67.9 (range: 48–79) | .81 |
| Gleason score | |||
| 2–7 | 34 (49%) | 50 (55%) | .56 |
| 8–10 | 36 (51%) | 42 (45%) | |
| Clinical stage | |||
| T2c | 20 (29%) | 44 (48%) | .005 |
| T3 | 50 (71%) | 48 (52%) | |
| Total dose | 70.1 Gy | 70.3 Gy | .22 |
| PSA (ng/mL) | |||
| <30 | 25 (36%) | 41 (44%) | .32 |
| >30 | 45 (64%) | 51 (56%) | |
| %N+ | |||
| <30% | 19 (27%) | 38 (41%) | .088 |
| >30% | 51 (73%) | 54 (59%) | |
| Duration of L-ADT (months) | 28.4 | 29.1 | .13 |
| Median followup (months) | 54 | 55 | .21 |
WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only, PSA: prostate specific antigen, N-ADT: neoadjuvant androgen deprivation therapy, L-ADT: long-term adjuvant androgen deprivation therapy, %N+: probability of metastases to pelvic lymph nodes calculated according to the Roach formula [18].
*Unpaired t-test for continuous variables; chi-square test for categorical variables.